Paclitaxel Neuropathy Protein Signals
In this exploratory study, rising NfL was associated with paclitaxel-induced peripheral neuropathy as early as three weeks after treatment initiation, while galectin-3 was not; proteomics also associated ADH4 upregulation and VOPP1 downregulation with neuropathy.
> Research explainer: This briefing examines verified primary research published 74 days before the briefing date. It is not a same-day research update and does not provide medical advice.
Evidence
This Research explainer concerns an exploratory study published on 2026-06-16 in patients with breast cancer receiving, or having received, paclitaxel-based therapy. The investigators examined neurofilament light chain (NfL) and galectin-3 as candidate blood biomarkers and used proteomic analysis to identify proteins associated with chemotherapy-induced peripheral neuropathy (CIPN). [pmid:42382318]
The study used two cohorts. One included patients scheduled to start paclitaxel or albumin-bound paclitaxel–containing chemotherapy and collected blood samples longitudinally. The other included patients receiving or previously treated with taxane-based chemotherapy who had clinically graded peripheral sensory neuropathy. [pmid:42382318]
Among participants who developed CIPN, NfL levels significantly increased as early as three weeks after treatment initiation. [pmid:42382318] NfL levels were also reported as markedly higher in participants with CIPN than in those without CIPN. [pmid:42382318] These observations make NfL the study’s principal candidate signal for early detection of CIPN during paclitaxel treatment. [pmid:42382318]
Galectin-3 did not show reported longitudinal changes or between-group differences in this study. [pmid:42382318] That contrast matters: the investigation evaluated both proteins, but its reported results support different interpretations for each candidate biomarker. [pmid:42382318]
The proteomic analysis identified upregulation of alcohol dehydrogenase 4 (ADH4) and downregulation of vesicular overexpressed in cancer prosurvival protein 1 (VOPP1) in association with CIPN. [pmid:42382318] The authors described these proteins as potentially associated with CIPN development rather than as validated diagnostic markers. [pmid:42382318]
Analysis — Biomarker Interpretation and Proteomic Context
The central contribution is not that NfL establishes CIPN on its own, but that its longitudinal increase tracked with neuropathy in the studied paclitaxel-treated breast-cancer population and appeared by week three. [pmid:42382318] A longitudinal measure can be especially informative in an exploratory biomarker design because it asks whether a protein changes over treatment, rather than only whether one measurement differs across people. The supplied evidence supports an association between increasing NfL and CIPN; it does not establish a threshold, a testing schedule, or a clinical decision rule. [pmid:42382318]
The negative galectin-3 result narrows the interpretation of this particular dataset. Although galectin-3 was evaluated as a candidate biomarker, no reported change or difference between CIPN groups was observed. [pmid:42382318] It therefore should not be presented as a supported signal from this study. Equally, that finding does not resolve galectin-3’s role in every setting; the evidence only describes the study population and analyses supplied here. [pmid:42382318]
ADH4 and VOPP1 extend the work from targeted candidate biomarkers to hypothesis-generating proteomics. The authors linked the ADH4 increase and VOPP1 decrease to oxidative stress and disrupted mitochondrial dynamics in their interpretation of CIPN pathogenesis. [pmid:42382318] Those links are biologically oriented interpretations, not proof that either protein causes neuropathy or that either pathway is the operative cause in an individual. The more restrained reading is that the proteins provide leads for replication, mechanistic experiments, and studies designed to test whether their measurements add information beyond NfL. [pmid:42382318]
Taken together, the results distinguish an associated longitudinal marker (NfL), an evaluated marker without reported discrimination (galectin-3), and two proteins associated with CIPN in a proteomic screen (ADH4 and VOPP1). [pmid:42382318] This framing preserves the study’s exploratory nature and avoids converting protein associations into clinical claims.
Limitations
The source explicitly describes the work as exploratory, so the findings establish associations and candidate biomarkers rather than clinical validation or causal mechanisms. [pmid:42382318] The supplied material does not provide sample sizes, effect sizes, diagnostic-performance measures, or enough methodological detail to assess reproducibility or generalizability. [pmid:42382318] It also concerns breast-cancer patients treated with paclitaxel or paclitaxel-containing therapy; extrapolation to other cancers, regimens, or neuropathy causes is unsupported by the supplied evidence. [pmid:42382318]
The mechanistic references to oxidative stress and mitochondrial dynamics are the authors’ bounded interpretations of proteomic findings, not demonstrated causal pathways. [pmid:42382318] This briefing does not provide medical advice, predict outcomes, or draw patient-specific conclusions.